Epitalon evidence check
Epitalon extends human lifespan.
Verdict
Unsupported with an evidence grade of F. Cell-line and aging-marker discussions do not establish that Epitalon extends human lifespan. Public longevity claims should be treated as unsupported unless controlled human outcome evidence is attached.
What this means
This grade applies only to the claim on this page, including the stated population and outcome. A supported claim in one context should not be stretched into a broader peptide promise.
What this does not mean
This page is not dosing guidance, a protocol, a recommendation to buy or use a product, or personal medical advice. High-risk claims need narrow wording, source links, and human review before publication.
Source trail
Evidence is listed by source type so you can see whether the claim rests on labeling, human studies, preclinical work, anecdotes, or vendor language.
Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations.
Drug-testing source relevant to illegal preparation and regulatory-risk context for Epitalon claims.
Open sourceEpitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.
Cell-line source for telomere-related mechanisms; not evidence of human lifespan extension.
Open sourceDisclosure
Disclosure: Some links may be affiliate links. Peptide Fact Checks may earn a commission if you use them. That does not affect evidence grades, verdicts, or vendor transparency notes.